Skip to main content


Everolimus-Eluting Platinum Chromium Coronary Stent System

Outstanding Safety and Performance with the SYNERGY Bioabsorbable Polymer (BP) Stent

Watch how the unique abluminal, bioabsorbable polymer with synchronous drug-elution and polymer absorption has shown healing and safety benefits.

Zero In on Safety

ARC Definite Stent Thrombosis Rates for the SYNERGY BP Stent1*

Late and Very Late stent thrombosis rates ranging from 0-0.2% in every clinical trial report thus far

1. SWEET Registry: Cook TCT 2015., Fribourg Experience: Arroyo CRT 2016. Belfast Experience: Noad TCT 2015., EVOLVE II: Kereiakes, et al. Circ Cardiovasc Interv. 2015;8:e002372. doi:10.1161/CIRCINTERVENTIONS.114.002372.,EVOLVE FHU: Meredith et al. J Am Coll Cardiol. 2012;59(15):1362., EVOLVE II QCA: Meredith ACC 2015., SCAAR Registry: James TCT 2016 BIO-RESORT presented by Clemens von Birgelen, MD, PhD, TCT 2016.

SYNERGY BP Stent Ranked #1 for Lowest Relative Risk of Definite/Probable Stent Thrombosis2*

The Kang et al (2016) meta-analysis is the most comprehensive network meta-analysis comparing contemporary coronary stents and scaffolds to date.

  • The study compared definite/probable stent thrombosis at 1-year between all study stents, which included data from 110 randomized controlled trials and 111,088 patients.
  • The primary endpoint was definite or probable stent thrombosis at 1-year.
  • The SYNERGY BP Stent ranked #1 for lowest relative risk of stent thrombosis, followed by the Promus PREMIER™ Permanent Polymer Stent ranked at #2.2

Promus PREMIER PP Stent vs. Comparators

2. Kang, al. J Am Coll Cardiol Intv.  doi:10.1016/j.jcin.2016.03.038

* Caution should be taken in interpreting study results, as some stents had limited numbers of comparisons, and some of the studies had a potential risk of bias. All PtCr-EES stents, also includes PROMUS Element and PROMUS Element Plus. Def/prob ST was available in 110 studies with 111,088 patients.


The SYNERGY BP Stent is supported by the long-term clinical trial results from the EVOLVE and EVOLVE II Trials. View the results >


Real-World Studies

Real-World Studies

Low event rates in real-world studies

Clinical Program

Clinical Program

Trial data and ongoing research

Early Healing

Early Healing

Advanced design for optimal healing